โ† All deals

Disc Medicine, Inc.

Public Equity (Nasdaq)BiopharmaceuticalClinical-StageHematology
๐Ÿ“ Watertown, Massachusetts, United Statesโ€ข Founded 2017
StreetZero Signal 61
Be the first to signal interest

About Disc Medicine, Inc.

Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. The company is building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. It is headquartered in Watertown, Massachusetts.

LATEST FUNDINGRule 144
$819K
Announced 2026-10-19
TOTAL RAISED$140M
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Disc Medicine, Inc..

Free plan includes 3 full deal profiles every month.

Key highlights

  • Completed $250M upsized public offering of common stock and pre-funded warrants in October 2025.
  • Raised total $140M over 4 rounds with latest Post-IPO round in Feb 2023.
  • Clinical-stage company targeting heme biosynthesis and iron homeostasis for hematologic diseases.
  • Publicly traded on Nasdaq under ticker IRON with market cap around $2.7B.
  • Headquartered in Watertown, MA with 14 institutional investors.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account